Cargando…
Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab
Trans-arterial radioembolization (TARE) with Y-90 microspheres is an endovascular, liver-directed therapy suitable for treatment of locally advanced hepatocellular carcinoma (HCC) often as a way to reduce tumor size and bridge patients to resection or liver transplant. Opdivo®, or nivolumab, a progr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467433/ https://www.ncbi.nlm.nih.gov/pubmed/31019861 http://dx.doi.org/10.7759/cureus.4083 |
_version_ | 1783411273868771328 |
---|---|
author | Adcock, Charles S Puneky, Louis V Campbell, Garth S |
author_facet | Adcock, Charles S Puneky, Louis V Campbell, Garth S |
author_sort | Adcock, Charles S |
collection | PubMed |
description | Trans-arterial radioembolization (TARE) with Y-90 microspheres is an endovascular, liver-directed therapy suitable for treatment of locally advanced hepatocellular carcinoma (HCC) often as a way to reduce tumor size and bridge patients to resection or liver transplant. Opdivo®, or nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, is an immunotherapeutic drug approved in September 2017 for the treatment of HCC in patients who have received prior sorafenib. We report on a patient with hepatocellular carcinoma with right and left portal vein involvement, bony metastasis, and possible lung metastasis. The patient showed a significant response following consecutive treatment with TARE, sorafenib, and nivolumab. Our case suggests that TARE, sorafenib, and nivolumab may have a synergistic effect on the immune response to HCC. |
format | Online Article Text |
id | pubmed-6467433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-64674332019-04-24 Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab Adcock, Charles S Puneky, Louis V Campbell, Garth S Cureus Radiation Oncology Trans-arterial radioembolization (TARE) with Y-90 microspheres is an endovascular, liver-directed therapy suitable for treatment of locally advanced hepatocellular carcinoma (HCC) often as a way to reduce tumor size and bridge patients to resection or liver transplant. Opdivo®, or nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, is an immunotherapeutic drug approved in September 2017 for the treatment of HCC in patients who have received prior sorafenib. We report on a patient with hepatocellular carcinoma with right and left portal vein involvement, bony metastasis, and possible lung metastasis. The patient showed a significant response following consecutive treatment with TARE, sorafenib, and nivolumab. Our case suggests that TARE, sorafenib, and nivolumab may have a synergistic effect on the immune response to HCC. Cureus 2019-02-16 /pmc/articles/PMC6467433/ /pubmed/31019861 http://dx.doi.org/10.7759/cureus.4083 Text en Copyright © 2019, Adcock et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Radiation Oncology Adcock, Charles S Puneky, Louis V Campbell, Garth S Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab |
title | Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab |
title_full | Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab |
title_fullStr | Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab |
title_full_unstemmed | Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab |
title_short | Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab |
title_sort | favorable response of metastatic hepatocellular carcinoma to treatment with trans-arterial radioembolization followed by sorafenib and nivolumab |
topic | Radiation Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467433/ https://www.ncbi.nlm.nih.gov/pubmed/31019861 http://dx.doi.org/10.7759/cureus.4083 |
work_keys_str_mv | AT adcockcharless favorableresponseofmetastatichepatocellularcarcinomatotreatmentwithtransarterialradioembolizationfollowedbysorafenibandnivolumab AT punekylouisv favorableresponseofmetastatichepatocellularcarcinomatotreatmentwithtransarterialradioembolizationfollowedbysorafenibandnivolumab AT campbellgarths favorableresponseofmetastatichepatocellularcarcinomatotreatmentwithtransarterialradioembolizationfollowedbysorafenibandnivolumab |